This is in line with a recent Drug Safety Update article from the MHRA, which discussed reports of capillary leak syndrome (CLS) in recipients of filgrastim and pegfilgrastim (other G-CSF products). Prescribers are advised to monitor patients and healthy donors for signs and symptoms of CLS, and give standard symptomatic treatment immediately if symptoms occur.